Wedbush Reiterates Outperform on Fusion Pharmaceuticals, Maintains $13 Price Target
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst David Nierengarten has reiterated an Outperform rating on Fusion Pharmaceuticals (NASDAQ:FUSN) and maintained a $13 price target.
June 28, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Fusion Pharmaceuticals has received an Outperform rating from Wedbush, with a maintained price target of $13.
The Outperform rating from Wedbush indicates a positive outlook for Fusion Pharmaceuticals. The maintained price target of $13 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100